MKP1 Antibody

Introduction to MKP1 Antibody

MKP1 (Mitogen-activated protein kinase phosphatase 1), also known as DUSP1, is a dual-specificity phosphatase that dephosphorylates and inactivates MAP kinases (MAPKs), including ERK, JNK, and p38. MKP1 antibodies are critical tools for studying this enzyme’s role in regulating immune responses, cancer progression, and cellular stress pathways . These antibodies enable researchers to detect MKP1 expression, localization, and post-translational modifications in experimental models and clinical samples.

Biochemical Properties and Development

MKP1 antibodies are developed using immunogens such as recombinant human/mouse MKP1 proteins or synthetic peptides. Key characteristics include:

Phospho-specific antibodies, such as those targeting phosphorylated Ser323 in MKP1, are used to study its activation state .

Applications in Research

MKP1 antibodies are indispensable for:

• Immune Regulation Studies: Tracking MKP1’s role in limiting pro-inflammatory cytokine production (e.g., TNF-α, IL-6) in macrophages and dendritic cells .

• Cancer Research: Assessing MKP1 expression in glioma stem cells (chemosensitivity) and colorectal cancer (cetuximab resistance) .

• Neurological Disorders: Investigating MKP1’s involvement in pain hypersensitivity via MAPK pathways .

Table 1: MKP1 Antibody-Driven Discoveries

Implications in Disease and Therapy

• Inflammatory Diseases: MKP1 deficiency exacerbates endotoxin-induced organ damage, highlighting its role as a therapeutic target for sepsis .

• Cancer Therapy: MKP1’s dual role—promoting chemosensitivity in gliomas but resistance in colorectal cancers —underscores context-dependent therapeutic strategies.

• Neuropathic Pain: MKP1 inhibition via miR-101 exacerbates pain hypersensitivity, suggesting MKP1 agonists as potential analgesics .